Asklepios BioPharmaceutical (AskBio) has secured an investment of $235m to accelerate its business of developing and manufacturing Adeno-Associated Virus (AAV) gene therapies for rare and generally untreatable genetic disorders.
Alnylam Pharmaceuticals and Regeneron Pharmaceuticals announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver.
Celltrion has entered into a partnership with iProgen Biotech, a pre-clinical stage Canadian biotechnology company, for the development of a series of antibody-drug conjugates against HER21 and CD20 and other validated antibody targets.
Alnylam Pharmaceuticals and Sanofi have agreed to conclude the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and LakePharma, Inc., the leading US-based biologics CRDMO, today announced a strategic collaboration to offer antibody discovery and development solutions to pharmaceutical and biotechnology customers.
Clinical-stage biopharmaceutical firm Xencor has entered into a research collaboration with Astellas Pharma for novel bispecific antibody program.
Swiss pharma giant Novartis has agreed to acquire IFM Tre from US biopharma company IFM Therapeutics in a deal worth up to $1.575bn, to add certain immunomodulatory medicines to its portfolio.
Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX (neratinib) within Europe and part of Africa.
Boehringer Ingelheim has acquired MacroDel biologics-delivery platform developer, ICD Therapeutics, for an undisclosed amount.
Major drugmaker AstraZeneca has entered into a $6.9bn cancer deal with Japanese pharmaceutical firm Daiichi Sankyo.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.